Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, ...

It also gave University of Michigan researchers a first look at how primary progressive multiple sclerosis, the fastest-progressing version of the disease, attacks the central nervous system early on.

It also gave researchers a look at how primary progressive multiple sclerosis, the fastest-progressing version of the disease, attacks the central nervous system early on. A sponge-like implant in ...